Home Bratislava Medical Journal 2013 Bratislava Medical Journal Vol.114, No.7, p.389-393, 2013

Journal info


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564


Aims and Scope
Editorial Info
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.114, No.7, p.389-393, 2013

Title: Portal vein embolization and application of autologous stem cells in patients with primary unresectable liver tumours
Author: V. Treska, V. Koza, D. Lysak, F. Slauf, H. Mirka, A. Sutnar, T. Skalicky, J. Fichtl, J. Ferda


Background: Only 15–20 % of patients with liver tumours can undergo radical surgery. Insufficient future liver remnant volume (FLRV) is one of the main causes of tumours unresectability. Portal vein embolization (PVE) together with administration of haematopoietic stem cells (HSC) may expand the operability of primary unresectable liver tumours.

Methods: In this pilot study, the authors reported on five patients (1 hepatocellular carcinoma, 4 colorectal cancer metastases) with FLRV <30 %, who underwent PVE on the side of the tumour with a subsequent application of HSC to the non-embolized branch of portal vein.

Results: PVE with HSC application was without any complications. In three patients, a sufficient increase of FLRV occurred within 2–4 weeks followed by a liver resection. All patients were between 5–12 months after the surgery in good condition; one of them was diagnosed with pulmonary metastasis after nine months that was successfully treated with laser metastasectomy. In one patient with hepatocellular carcinoma, an increase of FLRV and progression of the tumour in the liver occurred following the PVE with administration of HSC and the patient was treated only symptomatically. Despite an adequate increase of FLRV, severe intraabdominal adhesions hampered liver resection in one patient.
Conclusions: Combination of PVE with HSC administration appeared to be a promising method that stimulated growth of FLRV with a subsequent possibility of an early radical liver resection. The issue is a danger of tumour progression in the liver parenchyma following the PVE with HSC. The current randomized study should answer these questions (Tab. 1, Fig. 4, Ref. 38).

Keywords: unresectable liver tumours, portal vein embolization, haematopoietic stem cells
Year: 2013, Volume: 114, Issue: 7 Page From: 389, Page To: 393

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.